Gargallo, P. http://orcid.org/0000-0001-9720-8542
Bautista, F.
Juan-Ribelles, A.
Izquierdo, E.
Soriano, A.
de Rojas, T.
Escudero, A.
Lavarino, C.
Solano, P.
Hladun, R.
Rubio-San-Simón, A.
Martínez-Romera, I.
Calabria, I.
Olaciregui, N. G.
Castañeda-Heredia, A.
de Álava, E.
Pérez-Martínez, A.
Astigarraga, I.
Patiño-García, A.
Alonso, J.
Fernández-Teijeiro, A.
Cañete, A.
Moreno, L.
Funding for this research was provided by:
Bayer
Article History
Received: 25 October 2021
Accepted: 11 December 2021
First Online: 12 February 2022
Declarations
:
: LM is a member of data monitoring committees for clinical trials sponsored by Novartis, Actuate Therapeutics, Shionogi, Incyte, the University of Southampton and the Royal Marsden NHS Foundation Trust; and has had a consulting role for Novartis and Shionogi. LM is also member of the Executive Committee of SIOPEN (European neuroblastoma research cooperative group), an organization which receives royalties for the sales of dinutuximab beta. The remaining authors declare no conflict of interest.
: Not applicable.
: Not applicable.
: The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The manuscript does not contain clinical studies or patient data.